An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer

(2019) Shunji Takahashi et al.   Future Oncology

Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer

(2018) Nidal Al-Huniti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction

(2018) Takeshi Wada et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tivozanib for the treatment of renal cell carcinoma

(2018) Matteo Santoni et al.   EXPERT OPINION ON PHARMACOTHERAPY

VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive ProcessesNovelty and Significance

(2018) Karla B. Neves et al.   HYPERTENSION

Anti-Angiogenics: Current Situation and Future Perspectives

(2018) Katja Zirlik et al.   Oncology Research and Treatment

Left Ventricular Dysfunction in Cancer Treatment

(2018) Benjamin Kenigsberg et al.   JACC-Heart Failure

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience

(2018) Nilesh Pareek et al.   EUROPEAN JOURNAL OF HEART FAILURE

Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma

(2018) Midori Takada et al.   International Heart Journal

Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities

(2018) Maher Chaar et al.   OncoTargets and Therapy

Risk of regorafenib-induced cardiovascular events in patients with solid tumors

(2018) Jianxin Chen et al.   MEDICINE

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

(2018) Asghar Fallah et al.   BIOMEDICINE & PHARMACOTHERAPY

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats

(2017) Joanne J. Carter et al.   FASEB JOURNAL

Salt Sensitivity of Angiogenesis Inhibition–Induced Blood Pressure RiseNovelty and Significance

(2017) Stephanie Lankhorst et al.   HYPERTENSION

Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

(2017) Rhian M. Touyz et al.   HYPERTENSION

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

(2017) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells

(2017) Yu-xian Huang et al.   JOURNAL OF IMMUNOTHERAPY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Modulation of VEGF receptor 2 signaling by protein phosphatases

(2017) Federico Corti et al.   PHARMACOLOGICAL RESEARCH

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions

(2017) Diwakar Jain et al.   Current Cardiology Reports

Endothelin-1 and antiangiogenesis

(2016) Stephanie Lankhorst et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond

(2016) Rohit Moudgil et al.   CANADIAN JOURNAL OF CARDIOLOGY

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

(2016) A. B. Benson et al.   CLINICAL CANCER RESEARCH

Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art

(2016) Sandro Barni et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma

(2016) Elaine McWhirter et al.   INVESTIGATIONAL NEW DRUGS

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) Jonathan A Ledermann et al.   LANCET

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

(2016) Toni K Choueiri et al.   LANCET ONCOLOGY

Mechanisms and regulation of endothelial VEGF receptor signalling

(2016) Michael Simons et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cardiovascular Toxic Effects of Targeted Cancer Therapies

(2016) Javid J. Moslehi   NEW ENGLAND JOURNAL OF MEDICINE

Vascularization and Angiogenesis in Tissue Engineering: Beyond Creating Static Networks

(2016) Jeroen Rouwkema et al.   TRENDS IN BIOTECHNOLOGY

VEGF and Intraocular Neovascularization: From Discovery to Therapy

(2016) Napoleone Ferrara   Translational Vision Science & Technology

Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System

(2015) Antonella Moreo et al.   AMERICAN JOURNAL OF HYPERTENSION

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

(2015) J S L Kloth et al.   BRITISH JOURNAL OF CANCER

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

(2015) H. Hirte et al.   GYNECOLOGIC ONCOLOGY

Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With SunitinibNovelty and Significance

(2015) Stephanie Lankhorst et al.   HYPERTENSION

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

(2015) Juan W Valle et al.   LANCET ONCOLOGY

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) R Paul Symonds et al.   LANCET ONCOLOGY

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs

(2015) Nihay Laham-Karam et al.   Molecular Therapy-Nucleic Acids

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

(2014) P Ghatalia et al.   BRITISH JOURNAL OF CANCER

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

(2014) T. Dragovich et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial

(2014) Amikumar Mehta et al.   Future Oncology

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

(2014) Bradley J Monk et al.   LANCET ONCOLOGY

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

(2014) Robert J Motzer et al.   LANCET ONCOLOGY

A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

(2013) Rhonda L. Bitting et al.   Clinical Genitourinary Cancer

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

(2013) S.A. Laurie et al.   EUROPEAN JOURNAL OF CANCER

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

(2013) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

AKT2 Confers Protection Against Aortic Aneurysms and Dissections

(2012) Ying H. Shen et al.   CIRCULATION RESEARCH

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy

(2010) Javid Moslehi et al.   CIRCULATION

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

(2010) Emily S. Robinson et al.   HYPERTENSION

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

(2010) Vishnu Chintalgattu et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

(2009) Jane D. Robertson et al.   Clinical Colorectal Cancer

Cardiovascular toxicity of molecularly targeted agents

(2009) Elizabeth L. Strevel et al.   EUROPEAN JOURNAL OF CANCER

COX-2, VEGF and tumour angiogenesis

(2009) D.P. Toomey et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway

(2008) Leticia Oliveira-Ferrer et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH